INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10538104	
Filing Date		2005-06-08	_
First Named Inventor	Jens	Pollmann-Retsch, et al	
Art Unit		2821	
Examiner Name			_
Attorney Docket Numb	er	DE020302	Т

	Remove					
Examiner Initial*	kaminer Cite No Patent Number Kind Code1 Issue Date Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1 6016031 A 2000-01-18 LAPATOVICH ET AL					
	2 4672271 A 1997-06-09 GEAR GARY ET AL					
	3	5705897	97 A 1998-01-06 HANAZAKI YASUMASA ET AL		HANAZAKI YASUMASA ET AL	
	4	4 4887122 A 1989-12-12 MORIKAWA TAKESHI		MORIKAWA TAKESHI		
	5 4533583 A 1985-08-06 LAMA WILLIAM LET AL		LAMA WILLIAM L ET AL			
	6	5909085	A	1999-06-01	NELSON LEONARD Y	
7 5962990 A 1999-10-05 KERN ROBERT				KERN ROBERT		
If you wis	h to a	dd additional U.S. Pater	t citatio	n information pl	lease click the Add button.	Add
-					CATION PUBLICATIONS	Remove

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10538104		
Filing Date		2005-06-08		
First Named Inventor Jens		Pollmann-Retsch, et al		
Art Unit		2821		
Examiner Name				
Attorney Docket Numb	er	DE020302		

Date Considered

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	Name of Pat of cited Docu	entee or Applicant ument	Relev		Lines where ges or Relev	
	1										
If you wis	h to a	dd additional U.S. Publ	ished Ap	plication	citatio	n information p	please click the Add	butto	n. Add		_
				FOREIG	3N PAT	TENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patentee Applicant of cited Document		where Re	or Relevant	TS
	1	EP1017257			A1	2000-07-05	HONEYWELL INC				
	2	DE3019669			A1	1980-12-18	BELL & HOWELL	00			
If you wish	h to a	dd additional Foreign P	atent Do	cument	citation	information p	lease click the Add	buttor	Add		
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							Τs				
	1										
If you wis	h to a	dd additional non-pater	nt literatu	re docu	ment cit	tation informat	tion please click the	Add b	utton A	dd	_
				FX	AMINE	R SIGNATUR	rF.				_

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	10538104
	Filing Date	2005-06-08
	First Named Inventor Ja	ens Pollmann-Retsch, et al
	Art Unit	2821
	Examiner Name	
	Attorney Docket Number	DE020302

See for Codes of USPTO Patient Documents at your USPTO, CODE on MEPP 901.04. * Exister office that its sead no document, by the loss letter code (WPO) Standard 51.3. * For Legislance plants of comments, the indusion to the year of the region of the Engener patient control the seal number of the plant document. *
**India of courrent by the appropriate symbols as indicated on the document under WPO Standard 51.56 if possible. **
*India of courrent by the appropriate symbols as indicated on the document under WPO Standard 51.56 if possible. *
*India of courrent by the appropriate symbols as indicated on the document under WPO Standard 51.56 if possible. *
*India of courrent by the appropriate symbols as indicated on the document under WPO Standard 51.56 if possible. *
*India of courrent by the appropriate symbols as indicated on the document under the appropriate symbols are considered to the appropriate symbols are considered as a standard to the appropriate symbols are

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10538104		
Filing Date		2005-06-08		
First Named Inventor Jens		Pollmann-Retsch, et al		
Art Unit		2821		
Examiner Name				
Attorney Docket Number		DE020302		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97 a	and 1.98 to make t	the appropriate selection(s):
---------------	------------	--------------------	-------------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information siclosure statement. See 37 CFR 197(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(s)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Frank Keegan/	Date (YYYY-MM-DD)	2006-08-23
Name/Print	Frank Keecan	Registration Number	50145

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, and Superiment of Commence, P. 0. Bot 1450, Alexandria, V.32.511-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA.22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.